Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model

International Journal of Antimicrobial Agents

Volumn 42, Issue 3, 2013, Pages 220-225

  Baldoni, Daniela ^a   Furustrand Tafin, Ulrika ^b   Aeppli, Sandrine ^a   Angevaare, Eline ^a   Oliva, Alessandra ^b   Haschke, Manuel ^a   Zimmerli, Werner ^c   Trampuz, Andrej ^a,b,d  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c KANTONSSPITAL LIESTAL   (Switzerland)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Dalbavancin; Foreign body infection; Rifampicin; Staphylococcus aureus

Indexed keywords

DALBAVANCIN; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; GUINEA PIG; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

DALBAVANCIN; FOREIGN-BODY INFECTION; RIFAMPICIN; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GUINEA PIGS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PROSTHESES AND IMPLANTS; RIFAMPIN; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN;

EID: 84883454217     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.05.019     Document Type: Article

References (30)

1. A. Trampuz, and W. Zimmerli Prosthetic joint infections: update in diagnosis and treatment Swiss Med Wkly 135 2005 243 251
2. A.F. Widmer New developments in diagnosis and treatment of infection in orthopedic implants Clin Infect Dis 33 Suppl. 2 2001 S94 S106
3. C.R. Arciola, D. Campoccia, P. Speziale, L. Montanaro, and J.W. Costerton Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials Biomaterials 33 2012 5967 5982
4. A. Trampuz, and A.F. Widmer Infections associated with orthopedic implants Curr Opin Infect Dis 19 2006 349 356
5. P.S. Stewart, and J.W. Costerton Antibiotic resistance of bacteria in biofilms Lancet 358 2001 135 138
6. C.M. Brandt, M.C. Duffy, E.F. Berbari, A.D. Hanssen, J.M. Steckelberg, and D.R. Osmon Staphylococcus aureus prosthetic joint infection treated with prosthesis removal and delayed reimplantation arthroplasty Mayo Clin Proc 74 1999 553 558
7. F. Götz Staphylococcus and biofilms Mol Microbiol 43 2002 1367 1378
8. S. Schwank, Z. Rajacic, W. Zimmerli, and J. Blaser Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics Antimicrob Agents Chemother 42 1998 895 898
9. A.F. Widmer, A. Gaechter, P.E. Ochsner, and W. Zimmerli Antimicrobial treatment of orthopedic implant-related infections with rifampin combinations Clin Infect Dis 14 1992 1251 1253
10. G.L. Drusano, W. Liu, D.L. Brown, L.B. Rice, and A. Louie Impact of short-course quinolone therapy on susceptible and resistant populations of Staphylococcus aureus J Infect Dis 199 2009 219 226
11. A. Trampuz, and W. Zimmerli Antimicrobial agents in orthopaedic surgery: prophylaxis and treatment Drugs 66 2006 1089 1105
12. G.G. Zhanel, D. Calic, F. Schweizer, S. Zelenitsky, H. Adam, and P.R. Lagace-Wiens New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin Drugs 70 2010 859 886
13. A.Y. Chen, M.J. Zervos, and J.A. Vazquez Dalbavancin: a novel antimicrobial Int J Clin Pract 61 2007 853 863
14. B.P. Goldstein, D.C. Draghi, D.J. Sheehan, P. Hogan, and D.F. Sahm Bactericidal activity and resistance development profiling of dalbavancin Antimicrob Agents Chemother 51 2007 1150 1154
15. A. Malabarba, and B.P. Goldstein Origin, structure, and activity in vitro and in vivo of dalbavancin J Antimicrob Chemother 55 Suppl. 2 2005 ii15 ii20
16. S.W. Lin, P.L. Carver, and D.D. DePestel Dalbavancin: a new option for the treatment of Gram-positive infections Ann Pharmacother 40 2006 449 460
17. A. Kim, J.L. Kuti, and D.P. Nicolau Review of dalbavancin, a novel semisynthetic lipoglycopeptide Expert Opin Investig Drugs 16 2007 717 733
18. F. Van Bambeke, M.P. Mingeot-Leclercq, M.J. Struelens, and P.M. Tulkens The bacterial envelope as a target for novel anti-MRSA antibiotics Trends Pharmacol Sci 29 2008 124 134
19. D.P. Nicolau, H.K. Sun, E. Seltzer, M. Buckwalter, and J.A. Dowell Pharmacokinetics of dalbavancin in plasma and skin blister fluid J Antimicrob Chemother 60 2007 681 684
20. R.P. Rennie, L. Koeth, R.N. Jones, T.R. Fritsche, C.C. Knapp, and S.B. Killian Factors influencing broth microdilution antimicrobial susceptibility test results for dalbavancin, a new glycopeptide agent J Clin Microbiol 45 2007 3151 3154
21. A. Trampuz, C.K. Murphy, D.M. Rothstein, A.F. Widmer, R. Landmann, and W. Zimmerli Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection Antimicrob Agents Chemother 51 2007 2540 2545
22. Clinical and Laboratory Standards Institute Methods for susceptibility testing of anaerobic bacteria; approved standard 7th ed. 2007 CLSI Wayne, PA Document M11-A7
23. W. Zimmerli, F.A. Waldvogel, P. Vaudaux, and U.E. Nydegger Pathogenesis of foreign body infection: description and characteristics of an animal model J Infect Dis 146 1982 487 497
24. R.O. Darouiche, and M.D. Mansouri Dalbavancin compared with vancomycin for prevention of Staphylococcus aureus colonization of devices in vivo J Infect 50 2005 206 209
25. D. Jabes, G. Candiani, G. Romano, C. Brunati, S. Riva, and M. Cavaleri Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model Antimicrob Agents Chemother 48 2004 1118 1123
26. D. Andes, and W.A. Craig In vivo pharmacodynamic activity of the glycopeptide dalbavancin Antimicrob Agents Chemother 51 2007 1633 1642
27. A. Belley, E. Neesham-Grenon, G. McKay, F.F. Arhin, R. Harris, and T. Beveridge Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro Antimicrob Agents Chemother 53 2009 918 925
28. A.K. John, D. Baldoni, M. Haschke, K. Rentsch, P. Schaerli, and W. Zimmerli Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin Antimicrob Agents Chemother 53 2009 2719 2724
29. C. Garrigós, O. Murillo, G. Euba, R. Verdaguer, F. Tubau, and C. Cabellos Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 54 2010 5251 5256
30. C. Garrigós, O. Murillo, J. Lora-Tamayo, R. Verdaguer, F. Tubau, and C. Cabellos Efficacy of daptomycin-cloxacillin combination in experimental foreign-body infection due to methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 56 2012 3806 3811